JP2016503655A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503655A5
JP2016503655A5 JP2015550820A JP2015550820A JP2016503655A5 JP 2016503655 A5 JP2016503655 A5 JP 2016503655A5 JP 2015550820 A JP2015550820 A JP 2015550820A JP 2015550820 A JP2015550820 A JP 2015550820A JP 2016503655 A5 JP2016503655 A5 JP 2016503655A5
Authority
JP
Japan
Prior art keywords
sequence
listeria
residues
polynucleotide
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/078119 external-priority patent/WO2014106123A1/en
Publication of JP2016503655A publication Critical patent/JP2016503655A/ja
Publication of JP2016503655A5 publication Critical patent/JP2016503655A5/ja
Pending legal-status Critical Current

Links

JP2015550820A 2012-12-27 2013-12-27 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 Pending JP2016503655A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US61/746,237 2012-12-27
US201361780744P 2013-03-13 2013-03-13
US61/780,744 2013-03-13
PCT/US2013/078119 WO2014106123A1 (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018074066A Division JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Publications (2)

Publication Number Publication Date
JP2016503655A JP2016503655A (ja) 2016-02-08
JP2016503655A5 true JP2016503655A5 (enExample) 2017-02-16

Family

ID=51017446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015550820A Pending JP2016503655A (ja) 2012-12-27 2013-12-27 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用
JP2018074066A Expired - Fee Related JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018074066A Expired - Fee Related JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Country Status (12)

Country Link
US (2) US9663557B2 (enExample)
EP (1) EP2938627B1 (enExample)
JP (2) JP2016503655A (enExample)
KR (1) KR102160322B1 (enExample)
CN (1) CN104955835B (enExample)
AU (2) AU2013370210B2 (enExample)
BR (1) BR112015015076A2 (enExample)
CA (1) CA2888727A1 (enExample)
EA (1) EA201590397A8 (enExample)
MX (1) MX2015008329A (enExample)
SG (2) SG11201502792TA (enExample)
WO (1) WO2014106123A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
HRP20220890T1 (hr) * 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
HK1250662A1 (zh) * 2015-04-13 2019-01-11 Aduro Biotech, Inc. 用於治疗癌症的免疫原性融合蛋白
CA2982533A1 (en) * 2015-04-13 2016-10-20 Aduro Biotech, Inc. Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
US11066453B2 (en) 2015-05-18 2021-07-20 Biomvis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
IL280430B2 (en) * 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
JP7284156B2 (ja) 2017-09-19 2023-05-30 アドバクシス, インコーポレイテッド 細菌またはListeria株の凍結乾燥のための組成物および方法
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US20210003558A1 (en) 2018-03-09 2021-01-07 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of listeria strains
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3785029A1 (en) 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
JP7584299B2 (ja) 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
AU2021297245A1 (en) 2020-06-23 2023-02-02 Illumina Software, Inc. Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
CA2460014A1 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
KR20060130038A (ko) 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 EphA2 백신
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
GB2451014B (en) 2006-03-01 2010-12-29 Anza Therapeutics Inc Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine
WO2008008311A1 (en) 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
CA2724649A1 (en) * 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comprising prfa* mutant listeria and methods of use thereof
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
DK2640842T3 (en) 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
CA2829960A1 (en) * 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria

Similar Documents

Publication Publication Date Title
JP2009540801A5 (enExample)
JP2013526837A5 (enExample)
JP2014527404A5 (enExample)
KR102160322B1 (ko) 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도
JP2017511135A5 (enExample)
JP2017513502A5 (enExample)
JP2016501829A5 (enExample)
JP2014534202A5 (enExample)
JP5740473B2 (ja) ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
JP2019524150A5 (enExample)
JP2012515557A5 (enExample)
JP2011529077A (ja) C型肝炎の治療のための組成物および方法
JP2013501038A5 (enExample)
JP2018528237A5 (enExample)
RU2016136855A (ru) Биомаркер-направленная многоцелевая иммунотерапия
JP7146926B2 (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
WO2007119279A1 (ja) コイヘルペスウイルス(khv)病用dnaワクチン
JP2015524413A5 (enExample)
JP2021507712A5 (enExample)
JP2012102105A5 (enExample)
JP2012532626A5 (enExample)
JP2018533908A5 (enExample)
JP6213969B2 (ja) 免疫原性ポリペプチド表層発現ビフィズス菌
JP6975716B2 (ja) 樹状細胞標的化ペプチド、当該ペプチドを利用したペプチド融合体、及び当該ペプチド融合体を利用したワクチン
CN103266121B (zh) 一种复制子dna疫苗载体及其构建方法与应用